Shots:Axsome Therapeutics has reported P-III (FOCUS) trial data assessing solriamfetol (150 or 300mg, QD) vs PBO for 6wks. to treat of ADHD adults (n=516) in the USTrial met its 1EP, with 150mg showing greater AISRS score reductions vs PBO at Wk. 6 (17.7 vs 14.3 mean point decrease); improvements began at Wk. 1,…
Shots: The US FDA has granted approval to the company’s QD extended-release oral suspension of Onyda XR (clonidine hydrochloride) with nighttime dosing alone or as adj. to approved central nervous system (CNS) stimulant therapies for ADHD treatment in children (≥6yrs.). Its availability is anticipated in H2’24 The approval was supported by the data from studies…
Attention-Deficit/Hyperactivity Disorder (ADHD) is a common neurological condition that affects both children and adults. It manifests as inattention, impulsivity, and hyperactivity that impact daily functioning and development. Finding the right treatment is crucial as it can greatly improve the individual's ability to function and their quality of life. Treatment options are diverse, ranging from various…

